These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30382479)

  • 1. A pilot evaluation of the expanded prostate cancer index composite for clinical practice (EPIC-CP) tool in Ontario.
    Brundage MD; Barbera L; McCallum F; Howell DM
    Qual Life Res; 2019 Mar; 28(3):771-782. PubMed ID: 30382479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy.
    Wagner AA; Cheng PJ; Carneiro A; Dovirak O; Khosla A; Taylor KN; Crociani CM; McAnally KC; Percy A; Dewey LE; Sanda MG; Chang P
    J Urol; 2017 Jan; 197(1):109-114. PubMed ID: 27475967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piloting prostate cancer patient-reported outcomesin clinical practice.
    Korzeniowski M; Kalyvas M; Mahmud A; Shenfield C; Tong C; Zaza K; Howell D; Brundage M
    Support Care Cancer; 2016 May; 24(5):1983-1990. PubMed ID: 26498748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
    Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
    J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial.
    Tran C; Dicker A; Leiby B; Gressen E; Williams N; Jim H
    J Med Internet Res; 2020 Mar; 22(3):e12689. PubMed ID: 32209536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
    Lee JY; Daignault-Newton S; Heath G; Scarlett S; Sanda MG; Chang P; Regan MM; Michalski JM; Sandler HM; Feng FY; Kuban DA; Zietman AL; Ciezki JP; Kaplan ID; Crociani C; McLaughlin WP; Mantz CA; Finkelstein SE; Suy S; Collins SP; Garin O; Ferrer M; Hamstra DA; Spratt DE
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):770-777. PubMed ID: 27663760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    Protopapa E; van der Meulen J; Moore CM; Smith SC
    BJU Int; 2017 Oct; 120(4):468-481. PubMed ID: 28437031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An observational study evaluating the impact on prostate patient outcomes and experiences when radiation therapists use a standard grading system tool to assess and document treatment-related toxicities and interventions.
    Leung E; Fineberg H; Larsen T; Yaver M; Foo A; Ma J; Versloot J; Minotti SC
    J Med Imaging Radiat Sci; 2022 Sep; 53(3):444-452. PubMed ID: 35850922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of life in patients with prostate cancer: validation of an instrument for clinical practice].
    Balbontín F; Marchetti P; Moreno S; Cabello JM; Urzúa C; Silva A; Avilés J; Badínez L; García J; Salgado A; Vinez E; Alliende I; Canals A; Velasco A
    Arch Esp Urol; 2015 Jun; 68(5):466-73. PubMed ID: 26102050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The implementation of a novel patient symptom screening tool: The Odette Cancer Centre (OCC) experience.
    Turner A; Burlein-Hall S; Gandhi M
    J Med Imaging Radiat Sci; 2020 Dec; 51(4):546-549. PubMed ID: 32943361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.
    Axcrona K; Nilsson R; Brennhovd B; Sørebø Ø; Fosså SD; Dahl AA
    BMC Urol; 2017 Dec; 17(1):111. PubMed ID: 29197360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument.
    Rodrigues G; Bauman G; Venkatesan V; Ahmad B; Lock M; Sexton T; D'Souza D; Stitt L; Eid S
    Can J Urol; 2011 Aug; 18(4):5802-10. PubMed ID: 21854712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.
    Anota A; Mariet AS; Maingon P; Joly F; Bosset JF; Guizard AV; Bittard H; Velten M; Mercier M
    Health Qual Life Outcomes; 2016 Dec; 14(1):168. PubMed ID: 27923377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution.
    Lourenço DB; Amaral BS; Alfer-Junior W; Vasconcellos A; Russo F; Sanchez-Salas R; Bianco B; Wagner AA; Chang P; Moschovas MC; Lemos GC; Carneiro A
    BMC Urol; 2020 Oct; 20(1):163. PubMed ID: 33081748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.
    Chipman JJ; Sanda MG; Dunn RL; Wei JT; Litwin MS; Crociani CM; Regan MM; Chang P;
    J Urol; 2014 Mar; 191(3):638-45. PubMed ID: 24076307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of implementing a cervix cancer-specific patient-reported outcome measure in routine ambulatory clinics.
    Atallah S; Barbera L; Folwell M; Howell D; Liu Z; Croke J
    Support Care Cancer; 2021 Jan; 29(1):499-507. PubMed ID: 32405964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of point-of-care PRO assessment in clinic settings: integration, parallel-forms reliability, and patient acceptability of electronic QOL measures during clinic visits.
    Sharma P; Dunn RL; Wei JT; Montie JE; Gilbert SM
    Qual Life Res; 2016 Mar; 25(3):575-83. PubMed ID: 26373852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.
    Chang P; Szymanski KM; Dunn RL; Chipman JJ; Litwin MS; Nguyen PL; Sweeney CJ; Cook R; Wagner AA; DeWolf WC; Bubley GJ; Funches R; Aronovitz JA; Wei JT; Sanda MG
    J Urol; 2011 Sep; 186(3):865-72. PubMed ID: 21788038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving an electronic system for measuring PROs in routine oncology practice.
    Wu AW; White SM; Blackford AL; Wolff AC; Carducci MA; Herman JM; Snyder CF;
    J Cancer Surviv; 2016 Jun; 10(3):573-82. PubMed ID: 26644190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
    Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
    BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.